

1 **Antimicrobial susceptibility of *Flavobacterium psychrophilum* isolates**
2 **from the United Kingdom**

3 T P H Ngo¹, P Smith², K L Bartie¹, K D Thompson³, D W Verner-Jeffreys⁴, R Hoare¹, A
4 Adams¹

5 ¹ Institute of Aquaculture, University of Stirling, Stirling, UK

6 ² National University of Ireland, Galway, Ireland

7 ³ Moredun Research Institute, Pentlands Science Park, Penicuik, UK

8 ⁴ The Centre for Environment, Fisheries and Aquaculture Science, The Nothe,
9 Weymouth, UK

10

11 **Correspondence:** *T P H Ngo, Institute of Aquaculture, University of Stirling, Stirling*

12 *FK9 4LA (e-mail: nhpthao.snn@tphcm.gov.vn)*

13

14 This is the peer reviewed version of the following article: Ngo TPH, Smith P, Bartie KL, et al.
15 Antimicrobial susceptibility of *Flavobacterium psychrophilum* isolates from the United Kingdom.
Journal of Fish Diseases 2018;41:309–320, which has been published in final form at
<https://doi.org/10.1111/jfd.12730>. This article may be used for non-commercial purposes in
accordance With Wiley Terms and Conditions for self-archiving.

16 **Abstract**

17 Routine application of antimicrobials is the current treatment of choice for rainbow trout
18 fry syndrome (RTFS) or bacterial coldwater disease (BCWD) caused by *Flavobacterium*
19 *psychrophilum*. In this study, the antimicrobial susceptibilities of 133 *F. psychrophilum*
20 isolates, 118 of which were from the UK, were evaluated by broth microdilution and disc
21 diffusion methods following VET04-A2 and VET03-A guidelines of Clinical and
22 Laboratory Standards Institute (CLSI), respectively. Isolates were categorised as wild
23 type (fully susceptible, WT) or non-wild type (NWT) using normalised resistance
24 interpretation (NRI) determined cut-off values (CO_{WT}). Broth microdilution testing
25 showed that only 12% of UK isolates were WT to oxolinic acid ($MIC\ CO_{WT} \leq 0.25\text{ mg L}^{-1}$)
26 and 42% were WT for oxytetracycline ($MIC\ CO_{WT} \leq 0.25\text{ mg L}^{-1}$). In contrast, all the
27 isolates tested were WT ($MIC\ CO_{WT} \leq 2\text{ mg L}^{-1}$) for florfenicol, the main antimicrobial
28 for RTFS control in the UK. Disc diffusion-based CO_{WT} values were $\geq 51\text{ mm}$ for 10 μg
29 amoxicillin, $\geq 44\text{ mm}$ for 30 μg florfenicol, $\geq 30\text{ mm}$ for 2 μg oxolinic acid and $\geq 51\text{ mm}$
30 for 30 μg oxytetracycline. There was a high categorical agreement between the
31 classifications of the isolates by two testing methods for florfenicol (100%),
32 oxytetracycline (93%), and oxolinic acid (99%).

33

34 *Keywords:* *Flavobacterium psychrophilum*, antimicrobial susceptibility, epidemiological
35 cut-off values, disc diffusion, broth microdilution, rainbow trout fry syndrome.

36 **Introduction**

37 *Flavobacterium psychrophilum*, a Gram-negative, filamentous, psychrotrophic bacterium,
38 is the aetiological agent of rainbow trout fry syndrome (RTFS) and bacterial coldwater
39 disease (BCWD), which was first described in USA in 1946 (Borg 1948). *F.*
40 *psychrophilum* infection has been found throughout North America, Europe and
41 elsewhere in Turkey, Australia, Peru, Japan and Korea (Barnes & Brown 2011). A
42 commercial vaccine against RTFS/BCWD is still not available (Gómez *et al.* 2014).
43 Although phage therapy (Stenholm *et al.* 2008; Kim *et al.* 2010a; Castillo *et al.* 2012) and
44 the use of probiotic bacteria (StrömBesto & Wiklund 2011; Korkea-aho *et al.* 2011;
45 Boutin *et al.* 2012; Burbank *et al.* 2012) have been suggested to be a promising
46 alternative to the use of antibiotics in aquaculture, further studies are needed to prove the
47 consistent effect of these green/blue technologies on preventing the infection of *F.*
48 *psychrophilum*. Therefore, the use of antibiotics is currently the treatment of choice for
49 controlling RTFS/BCWD outbreaks, resulting in a concern about the development of
50 antimicrobial resistance by *F. psychrophilum* (Gómez *et al.* 2014). In the UK, three
51 antibiotics (florfenicol, oxytetracycline and amoxicillin) are licensed for use in
52 aquaculture by the UK Veterinary Medicines Directorate (VMD)
53 (<http://www.vmd.defra.gov.uk/>).

54 Several studies have examined the antimicrobial susceptibility of *F. psychrophilum*
55 isolated from the USA (Pacha 1968, Soule *et al.* 2005; Van Vliet *et al.* 2017), the UK
56 (Rangdale *et al.* 1997; Verner-Jeffreys & Taylor 2015; Smith *et al.* 2016), Denmark
57 (Lorenzen *et al.* 1997; Bruun *et al.* 2000; Dalsgaard & Madsen 2000; Schmidt *et al.*

58 2000; Bruun *et al.* 2003; Smith *et al.* 2016), France (Michel *et al.* 2003), Japan (Izumi &
59 Aranishi 2004), Turkey (Kum *et al.* 2008; Durmaz *et al.* 2012; Boyacioğlu & Akar 2012;
60 Boyacioğlu *et al.* 2015), Canada (Hesami *et al.* 2010), Spain (Del Cerro *et al.* 2010),
61 Norway (Nilsen *et al.* 2011), Chile (Henríquez-Núñez *et al.* 2012; Miranda *et al.* 2016)
62 and Finland (Sundell *et al.* 2013). However, differences in the medium and growth
63 conditions used in these studies and variations in the interpretive criteria used make
64 comparisons difficult. In addition, some of these studies included only a small number of
65 isolates, while others produced susceptibility data that was too diverse to allow any
66 estimate of cut-off values to interpret their meaning.

67 Smith *et al.* (2013) addressed the need for standardised and internationally
68 recognized protocols for laboratory *in vitro* susceptibility testing in monitoring and
69 surveillance programmes and the use of standardised methods to calculate
70 epidemiological cut-off values for interpretation of the meaning of the data collected in
71 such surveys.

72 The aim of the present study was to evaluate the antimicrobial susceptibility of 140
73 *F. psychrophilum* isolates, 125 of which were obtained within the UK, by the disc
74 diffusion and standardised broth microdilution methods following VET03-A (CLSI 2006)
75 and VET04-A2 (CLSI 2014a) guidelines respectively, as recommended by the Clinical
76 and Laboratory Standards Institute (CLSI) for aquatic bacteria with an optimal growth
77 temperature below 35°C.

78

79 **Materials and Methods**

80 **Bacterial isolates and growth conditions**

81 A total of 140 *F. psychrophilum* isolates, previously described by Ngo *et al.* (2017) for
82 genetic and serological diversity, were examined in this study. This collection comprised
83 125 isolates obtained within the UK during 2005-2015 and 15 isolates from other
84 countries (France, Denmark, Finland, Ireland, Chile and the USA) (Table 1 and 2); 123
85 *F. psychrophilum* isolates were obtained from rainbow trout (*Oncorhynchus mykiss*), 16
86 from Atlantic salmon (*Salmo salar*) and one from coho salmon (*O. kisutch*). *F.*
87 *psychrophilum* type strain NCIMB 1947^T (ATCC 49418^T) was included for comparative
88 purposes. For all the experiments, the *F. psychrophilum* isolates were grown in Modified
89 Veggietone (MV) medium [veggitones GMO-free soya peptone (Oxoid, UK), 5 g L⁻¹;
90 yeast extract (Oxoid, UK), 0.5 g L⁻¹; magnesium sulphate heptahydrate (Fisher chemicals,
91 UK), 0.5 g L⁻¹; anhydrous calcium chloride (BHD), 0.2 g L⁻¹; dextrose (Oxoid, UK), 2 g
92 L⁻¹; agar (solid medium; Oxoid, UK), 15 g L⁻¹; pH 7.3] at 18°C for 72 – 96 h. Broth
93 cultures were shaken at 140 rpm. Stock cultures were maintained at -70°C in tryptone–
94 yeast extract–salts medium supplemented with glucose [FLP – tryptone (Oxoid, UK), 4.0
95 g L⁻¹; yeast extract, 0.4 g L⁻¹; anhydrous calcium chloride, 0.2 g L⁻¹; magnesium sulphate
96 heptahydrate, 0.5 g L⁻¹; D(+)-glucose (Sigma, UK), 0.5 g L⁻¹; Cepeda *et al.* 2004] with
97 10% glycerol and on Protect-Multi-purpose cryobeads (Technical Service Consultants
98 Ltd, UK).

99 The 125 isolates from 27 sites within the UK in this study had been isolated
100 between 2005 and 2015 with the majority (110 strains, 88%) being retrieved between
101 2011 and 2013. Among these isolates, 51 genotypes and 7 plasmid profiles were detected

102 (Ngo *et al.* 2017) (Table 1). However, within this set of 125 isolates, there were five
103 groups of two or three isolates that were recorded as having the same site, sampling time
104 point, genetic profiles and susceptibilities. In order to avoid the over-representation, 7
105 potential replicates were eliminated from the analysis and only 118 UK isolates were
106 included in the analyses. The epidemiological cut-off values were calculated from the
107 data obtained from 118 UK isolates and 15 isolates from other countries. The frequencies
108 of NWT phenotypes circulating the UK during 2005 – 2015 were estimated from the
109 analysis of 118 isolates.

110

111 **Minimum inhibitory concentration (MIC) testing**

112 The MICs for *F. psychrophilum* isolates were performed using Sensititre CMP1MSP
113 plates (Trek Diagnostic Systems; ThermoScientific.com/microbiology). These test plates
114 were 96-well, dry-form plates that contained twofold serial dilutions of the following
115 antimicrobial agents: ampicillin (AMP) 0.03–16 mg L⁻¹, amoxicillin (AMOX) 0.25–16
116 mg L⁻¹, erythromycin (ERY) 0.25–128 mg L⁻¹, enrofloxacin (ENRO) 0.002–1 mg L⁻¹,
117 florfenicol (FFN) 0.03–16 mg L⁻¹, flumequine (FLUQ) 0.008–4 mg L⁻¹,
118 ormetoprim/sulphadimethoxine (PRI) 0.008/0.15–4/76 mg L⁻¹, oxolinic acid (OXO)
119 0.004–2 mg L⁻¹, oxytetracycline (OTC) 0.015–8 mg L⁻¹ and
120 trimethoprim/sulphamethoxazole (SXT) 0.015/0.3–1/19 mg L⁻¹.

121 The MIC assays were determined using the broth microdilution protocol
122 recommended for *F. psychrophilum* in the CLSI guideline VET04-A2 (CLSI 2014a).

123 Colony counts on inoculum suspensions were performed to ensure that the final inoculum
124 density was close to 5.0×10^5 colony-forming units (CFU) per millilitre.

125

126 **Disc diffusion testing**

127 Disc diffusion susceptibility of the *F. psychrophilum* strains was determined by the
128 protocol suggested in the guideline VET03-A (CLSI 2006) with modification on the agar
129 percentage of the culture medium. It should be noted, however, that this protocol has not
130 been formally accepted as a standard by CLSI. The test was performed on diluted
131 Mueller-Hinton medium (Sigma-Aldrich, UK; 3 g L^{-1}) containing 1.5% agar (Agar No.
132 1, LP0011, Oxoid, UK) (MHA) and 5% foetal calf serum (FCS; Gibco, Fisher
133 chemicals, UK) and plates were incubated at 15°C for 68 – 72 h. Antimicrobial agent
134 discs (Oxoid, Basingstoke, UK) containing 10 μg amoxicillin (AMOX₁₀), 5 μg
135 enrofloxacin (ENRO₅), 30 μg florfenicol (FFN₃₀), 2 μg oxolinic acid (OXO₂), 30 μg
136 oxytetracycline (OTC₃₀) and 25 μg trimethoprim/sulphamethoxazole (SXT₂₅) were
137 employed.

138

139 **Quality control**

140 As specified in VET04-A2 (CLSI 2014a) the quality control strain *Escherichia coli*
141 NCIMB 12210 (ATCC[®] 25922) was included in every MIC test run and was assayed on
142 diluted CAMHB at 18°C as described above. However, no quality control ranges have
143 been established for any disc diffusion protocol specifying these incubation conditions

144 (CLSI 2006). Therefore, the *F. psychrophilum* type strain NCIMB 1947^T was also
145 included in every test run to monitor the performance of the method.

146

147 **Statistical analysis**

148 The antimicrobial susceptibility patterns of 133 *F. psychrophilum* isolates used in this
149 study were analysed by application of protocol and species-specific epidemiological cut-
150 off values (CO_{WT}). These values allow isolates to be categorised as fully susceptible
151 (wild type, WT) or manifesting reduced susceptibility (non-wild type, NWT). In this
152 work, CO_{WT} values were calculated for both the MIC and disc diffusion data by the
153 normalised resistance interpretation (NRI) method (Kronvall 2003; 2010). This NRI
154 method was used with permission from the patent holder, Bioscand AB, TÄY, Sweden
155 (European patent No 1383913, US patent No 7,465,559).

156 MIC distributions were analysed using the NRI method of Kronvall (2010). A fully
157 automatic Excel spreadsheet for performing these NRI analyses is available on-line
158 (<http://www.bioscand.se/nri/>). In data sets where a small percentage (<5 %) of the WT
159 observations were “below-scale”, these observations were treated as having the MIC
160 value immediately below the limit of the plate quantitation. When the percentage of the
161 WT observations “below-scale” was >5%, the data set was considered as unsuitable for
162 NRI analysis (Smith *et al.* 2016).

163 The NRI analyses for zone histograms were performed using a modification of the
164 standardised protocol developed by Kronvall & Smith (2016). In this modification, the

165 peak values of the zone sizes for the putative WT isolates were established using 8-point
166 rather than 4-point rolling means.

167

168 **Terminology**

169 The acronyms ECV and ECOFF have been used by the CLSI and European Committee
170 on antimicrobial susceptibility testing (EUCAST) respectively for epidemiological cut-
171 off values set from data generated in multiple laboratories. In the present study, the term
172 CO_{WT}, as previously employed by Smith *et al.* (2016), was used to indicate
173 epidemiological cut-off values that have not been set by either of these international
174 agencies. It has been suggested that the terms resistant and sensitive should not be used to
175 refer to the categories identified by epidemiological cut-off values (Silley 2012).
176 Following this suggestion, when isolates are categorised by epidemiological cut-off
177 values, the terms wild type (WT) and non-wild type (NWT) should be used for fully
178 susceptible isolates and isolates exhibiting reduced susceptibility respectively.

179

180 **Results**

181 **Quality control**

182 The MIC values obtained with the quality control reference strain *E. coli* NCIMB 12210,
183 grown at 18°C for 72-96 h in diluted CAMHB, were within the acceptable range
184 published by CLSI in VET03/04-S2 guideline (CLSI 2014b). All the inoculum
185 suspensions used in MIC tests were confirmed to have the density ranging from 4.8×10^5
186 to 5.3×10^5 CFU mL⁻¹ by colony counts.

187 *F. psychrophilum* type strain NCIMB 1947^T was included in all disc diffusion tests
188 and the inhibition zone data of this strain were 56 – 72 mm for AMOX₁₀, 60 – 75 mm for
189 ENRO₅, 57 – 64 mm for FFN₃₀, 64 – 86 mm for OTC₃₀, 45 – 56 mm for OXO₂ and 16 –
190 44 mm for SXT₂₅. The mean of the ranges of these zone sizes for these six agents against
191 the *F. psychrophilum* type strain was 16.5 ± 7.6 mm.

192

193 **NRI analysis of susceptibility data**

194 The distribution of MIC values of 133 *F. psychrophilum* isolates for ten antimicrobial
195 agents is shown in Table 3 and 4. MIC-based CO_{WT} values of antimicrobial agents are
196 presented in Table 5. The distribution of disc diffusion zones of the isolates for six
197 antimicrobials is presented in Figure 1 and the zone data-based CO_{WT} values of
198 antimicrobial agents are shown in Table 6.

199

200 *Oxytetracycline*

201 MIC data for OTC showed a clear bimodal distribution (Table 3). The modal group with
202 lower MICs was assumed to represent the WT group. NRI analysis calculated the
203 standard deviation of the log₂ normalised WT distribution as 0.68 and a CO_{WT} value of
204 ≤ 0.25 mg L⁻¹ (Table 5). Applying this cut-off, fifty-six (42%) of the 133 isolates analysed
205 were categorised as WT.

206 The disc diffusion zone sizes for OTC₃₀ showed considerable diversity at the high
207 zone end (Figure 1A). However, NRI analysis of these data identified a high zone modal
208 group with a standard deviation of 7.44 mm. If this modal group was assumed to

209 represent zones obtained from WT isolates, a provisional CO_{WT} value of ≥ 51 mm could
210 be calculated (Table 6). Applying this cut-off, sixty-five (49%) of the 133 isolates
211 analysed were categorised as WT.

212 The categorisation of isolates resulting from applying the cut-off of ≤ 0.25 mg L⁻¹ to
213 the MIC data agreed with the categorisation resulting from applying the disc zone cut-off
214 of ≥ 51 mm to the zone data for 93% of the 133 isolates studied (Figure 2A).

215

216 *Amoxicillin and ampicillin*

217 For AMOX, 98 observations (100% of the lower MIC modal observations) and for AMP,
218 24 observations (24% of the lower MIC modal observations) were recorded as “below-
219 scale” (Table 3). On this basis, neither of these data sets was considered suitable for NRI
220 analysis.

221 As in MIC data set for AMP there was a clear separation of the low MIC and high
222 MIC modal groups, this data set was considered suitable for estimating CO_{WT} by visual
223 examination. The estimated value generated by this subjective method was ≤ 0.125 mg L⁻¹
224 for AMP. A scatterplot of the paired MIC data for these two beta-lactam agents (Figure
225 3A) suggested a high correlation between them and also demonstrated that AMOX might
226 have the same distribution as AMP.

227 The disc diffusion zone sizes for AMOX₁₀ were also bimodal (Figure 1B). NRI
228 analysis of these data calculated a standard deviation of the normalised WT distribution
229 of 5.2 mm and a CO_{WT} value of ≥ 56 mm (Table 6). A scatterplot of the paired MIC

230 values versus inhibition zone sizes for amoxicillin suggested a high correlation between
231 them (Figure 2B).

232

233 *Florfenicol*

234 MIC data for FFN showed a clear unimodal distribution (Table 3). This modal group was
235 assumed to represent the WT isolates. NRI analysis calculated a standard deviation of the
236 \log_2 normalised WT distribution of 0.68 and a CO_{WT} value of ≤ 2 mg L⁻¹ (Table 5).

237 The disc diffusion zone sizes for FFN₃₀ were also unimodal (Figure 1C). NRI
238 analysis of these data calculated a standard deviation of the normalised WT distribution
239 of 5.6 mm and a CO_{WT} value of ≥ 45 mm (Table 6).

240 Applying the cut-off of ≤ 2 mg L⁻¹ to the MIC data and the disc zone cut-off of ≥ 41
241 mm to the zone data categorised 100% of the 133 isolates studied as WT (Figure 2C).

242

243 *Oxolinic acid, Flumequine and Enrofloxacin*

244 The MIC values of OXO, FLUQ and ENRO were bimodally distributed (Table 3). NRI
245 analysis calculated the standard deviation of the \log_2 normalised WT distribution as 0.67,
246 0.57 and 0.74 for OXO, FLUQ and ENRO respectively. The MIC CO_{WT} values
247 calculated from these data were ≤ 0.25 mg L⁻¹ for OXO, ≤ 0.125 mg L⁻¹ for FLUQ and
248 ≤ 0.032 mg L⁻¹ for ENRO (Table 5). When these CO_{WT} values were applied, 21 (16%), 20
249 (15%) and 20 (15%) of the 133 isolates were categorised as WT with respect to OXO,
250 FLUQ and ENRO respectively.

251 Scatterplots of the MIC data for OXO against those for FLUQ and ENRO (Figure
252 3B and 3C) demonstrated a high (>97.7%) categorical agreement in both cases. This
253 suggests that it would be safe to accept MIC data for OXO as a predictor of reduced
254 susceptibility to the FLUQ and ENRO (Smith *et al.* 2016). Adoption of this proposal
255 would reduce the cost of routine susceptibility testing.

256 The disc diffusion zone sizes for OXO₂ were bimodal (Figure 1D). NRI analysis of
257 these data calculated a standard deviation of the normalised WT distribution of 8.5 mm.
258 This high standard deviation is probably a result of the fact that high zone modal group
259 was diverse and composed of only a few observations. This suggests that the disc CO_{WT}
260 value calculated by NRI analysis of ≥ 30 mm (Table 6) should only be treated as a
261 provisional value. Applying the cut-off of ≤ 0.25 mg L⁻¹ to the MIC data for OXO and the
262 disc zone cut-off of ≥ 30 mm to the zone data resulted in 99% agreement in the
263 categorisation of the 133 isolates studied (Figure 2D).

264 The disc diffusion zone sizes for FLUQ were not determined and those for ENRO
265 did not show any visually obvious high zone modal group and were not subject to NRI
266 analysis (Figure 1E).

267

268 *Erythromycin*

269 MIC values of ERY had a unimodal distribution. NRI analysis calculated a standard
270 deviation of the log₂ normalised WT distribution of 0.98 and the CO_{WT} value was
271 calculated as ≤ 8 mg L⁻¹ (Table 3 and 5). This value determined that all 133 *F.*

272 *psychrophilum* isolates analysed were WT for ERY.

273

274 *Ormetoprim/Sulphadimethoxine and Trimethoprim/Sulphamethoxazole*

275 The distributions of the MIC values for these two potentiated sulfonamide agents were
276 diverse but appeared to be unimodal (Table 3). NRI analysis generated provisional CO_{WT}
277 values for PRI and SXT of ≤ 320 mg L⁻¹ and ≤ 160 mg L⁻¹, respectively. However, the
278 standard deviations calculated for the normalized distribution of these putative WT
279 observations, $1.39 \log_2$ mg L⁻¹ and $1.67 \log_2$ mg L⁻¹ for PRI and SXT respectively, were
280 higher than those recorded for all other agents in this work (Table 5). Therefore, the
281 validity of these CO_{WT} values was questionable.

282 The disc diffusion zone sizes for SXT did not show any visually obvious high zone
283 modal group and were not subject to NRI analysis (Figure 1F).

284

285 **Discussion**

286 **Data precision**

287 *Precision of MIC data sets*

288 The precision of any CO_{WT} value is a function of the precision of the observational data
289 used to calculate it. Smith *et al.* (2012) demonstrated that the standard deviations of the
290 normalised distributions of the log₂ WT observation calculated by the NRI analysis could
291 provide a proxy measurement of precision. The median of the standard deviation
292 calculated for 22 *F. psychrophilum* data sets published by Michel *et al.* (2003), Smith *et*
293 *al.* (2016) and Van Vliet *et al.* (2017) was $0.70 \log_2$ mg L⁻¹. In this work, the median
294 value of standard deviations calculated for ENRO, ERY, FFN, FLUQ, OTC and OXO

295 (Table 5) was $0.72 \log_2 \text{ mg L}^{-1}$. This suggests that the MIC data sets obtained in this work
296 for these agents were of an acceptable level of precision and were of sufficient quality
297 that they could be used to calculate CO_{WT} values.

298 The standard deviations calculated for potentiated sulphonamide MIC data, 1.39
299 $\log_2 \text{ mg L}^{-1}$ and $1.61 \log_2 \text{ mg L}^{-1}$ for PRI and SXT respectively in this work, were,
300 however, considerably larger and were taken to indicate significant imprecision. Smith *et*
301 *al.* (2016) and Van Vliet *et al.* (2017), who used the same testing protocol as was used in
302 this work also reported very low precision in the MIC data they obtained for these agents
303 (mean $1.43 \log_2 \text{ mg L}^{-1}$). Due to their low precision, it was considered that valid CO_{WT}
304 could not be established for PRI and SXT data obtained in this work.

305

306 *Precision of disc diffusion data sets*

307 Smith & Kronvall (2015) analysed zone data for reference control strains *E. coli* ATCC
308 25922 and *Aeromonas salmonicida* ATCC 33658 and demonstrated a reduction in
309 precision as the incubation temperature decreased and time increased. Analysis of the
310 data obtained from the reference strain *F. psychrophilum* NCIMB 1947^T and from the test
311 isolates in this work suggest a similar effect of temperature and time on precision of zone
312 size data.

313 The mean of the ranges of zone sizes for the control reference strain *E. coli* NCIMB
314 12210 provided in the guideline VET03-A (CLSI 2006) for tests performed at 35°C ,
315 28°C and 22°C were $7.7 \pm 0.8 \text{ mm}$, $8.0 \pm 1.5 \text{ mm}$ and $11.8 \pm 2.0 \text{ mm}$ respectively (Smith

316 and Kronvall 2015). In this work, the mean range obtained at 15°C for six agents against
317 the control strain *F. psychrophilum* NCIMB 1947^T was 16.5 mm ± 7.6 mm

318 The mean of standard deviations of the 19 zone data sets obtained at 28°C in studies
319 of *Edwardsiella tarda* and *Vibrio harveyi* was 2.53 mm (Lim *et al.* 2016). For 13 data
320 sets of *A. salmonicida* obtained at 22°C, the mean was 3.9 mm (Miller & Reimschuessel
321 2006; Smith *et al.* 2007). In this work, the disc diffusion assays were performed at 15°C
322 and the mean standard deviation of the normalised distributions of the four disc data sets
323 was 6.7 mm.

324 These comparisons suggest that the low precision of the zone data sets obtained in
325 this work was most probably a function of the inherent property of this type of assay
326 rather than any laboratory specific errors in the performance of the assays. However, the
327 low level of precision suggests that any CO_{WT} calculated from these zone data should be
328 treated as only provisional estimates.

329

330 **Categorical agreements**

331 With the calculated MIC CO_{WT} and provisional disc diffusion-based CO_{WT} of FFN, OXO
332 and OTC, it is possible to calculate the percentage agreement between the categorisation
333 of the 133 isolates obtained by analysing the observed MIC measures and the zone size
334 data. The values of these categorical agreements were 100% for FFN, 99% for OXO and
335 93% for OTC. This high level of categorical agreement raise the possibility that, although
336 the disc diffusion protocol used in this work generated data of low precision, the

337 provisional CO_{WT} calculated from them may have some value in detecting isolates of
338 reduced susceptibility.

339 It should, however be noted that Smith & Kronvall (2015) demonstrated that
340 reduced temperatures and prolonged incubation time increased not only the level of intra-
341 laboratory variation but also the level of inter-laboratory variation in the data generated.
342 High inter-laboratory variation of the data will have the consequence that although any
343 provisional disc CO_{WT} calculated in one laboratory may have some value in interpreting
344 zone data produced in that laboratory, it may be misleading if applied to zone data
345 obtained in another laboratory. In other words, the CO_{WT} values for MIC data calculated
346 in this work are probably laboratory-independent and of general or ‘universal’
347 applicability. However, it is probably safer to treat the CO_{WT} values for inhibition zone
348 data generated in this work as only of local applicability. As a consequence, each
349 laboratory using this protocol to perform disc diffusion assays would have to generate
350 their own CO_{WT} values. The disc diffusion test protocol used in this work has not been
351 accepted as a standard by CLSI. It is possible that further optimisation such as using a
352 higher incubation temperature (18°C) may lead to a protocol with increased precision.

353

354 **Comparison of CO_{WT} values calculated for MIC measures determined by**
355 **standardised broth microdilution protocols of CLSI for *F. psychrophilum***

356 The values for any CO_{WT} are protocol-specific. It is, therefore, legitimate to compare the
357 CO_{WT} calculated in this work with those published by Smith *et al.* (2016) and Van Vliet
358 *et al.* (2017), who also used the standardised broth microdilution protocol (CLSI 2014a)

359 and NRI method to calculate CO_{WT} for *F. psychrophilum* from MIC data. This
360 comparison can be made with respect to three agents (FFN, OXO and OTC). For FFN
361 and OXO, the same CO_{WT} values (≤ 2 mg L⁻¹ and 0.25 mg L⁻¹ respectively) were
362 calculated from all three studies. For OTC, Smith *et al.* (2016) and Van Vliet *et al.* (2017)
363 calculated a CO_{WT} of ≤ 0.125 mg L⁻¹ compared to the 0.25 mg L⁻¹ calculated in this work.
364 It should, however, be noted that in this work, no isolates were recorded as manifesting
365 an MIC of 0.25 mg L⁻¹ for OTC (Table 3) and the categorisation of the 133 isolates
366 studied here would be the same if either CO_{WT} value was applied to them. This
367 agreement in the CO_{WT} values calculated illustrates the value of the use of standardised
368 test protocols and statistically based interpretive criteria and suggests that it should be
369 possible for CLSI to set internationally applicable, laboratory-independent ECVs for this
370 species.

371

372 **Frequencies of UK *F. psychrophilum* isolates with reduced susceptibility**

373 Applying the CO_{WT} values calculated or, in the case of AMP, estimated in this work
374 (Table 5) to the MIC data from these 118 UK *F. psychrophilum* isolates, the frequencies
375 of those with reduced susceptibility were 92% for FLUQ, 90% for ENRO, 88% for OXO,
376 58% for OTC, 32% for AMP and no isolates were recorded with reduced susceptibility
377 for FFN and ERY. However, as noted by Smith *et al.* (2016), ERY, a drug whose primary
378 value is in treating infections by gram-positive bacteria, has never been recommended for
379 the control of *F. psychrophilum* infections of aquatic animal. There have been two earlier
380 studies of NWT frequencies in UK *F. psychrophilum* isolates. Rangdale *et al.* (1997)

381 investigated the susceptibility of 47 *F. psychrophilum* isolates, 36 of which were
382 collected in the UK. However, their MIC data sets were of very low precision (mean log₂
383 standard deviation for FFN, OTC and OXO of 3.24 log₂ mg L⁻¹) and therefore, reliable
384 estimates of NWT frequencies could not be assessed. In a smaller study (27 UK *F.*
385 *psychrophilum* isolates) that used the same testing protocol and statistically based
386 interpretive criteria as used in this work, Smith *et al.* (2016) reported NWT frequencies
387 similar to those reported here. When the isolates studied here are combined those studied
388 by Smith *et al.* (2016), the frequency of NWT phenotypes in the 145 UK isolates
389 obtained during 2005 – 2015 were 85%, 59% for OXO and OTC respectively, and no
390 NWT phenotypes were reported for FFN.

391

392 **Antibiotic use in UK rainbow trout farming**

393 Verner-Jeffreys & Taylor (2015) reported the use of four agents (FFN, OXY, AMOX and
394 OXO) in attempts to control RTFS in the UK. The survey revealed that FFN was the
395 treatment of choice in the industry. These FFN treatments were generally considered very
396 effective. Where other antimicrobials (OTC, OXO or AMOX) were used, the therapeutic
397 response was reported as either mixed or poor.

398 These anecdotal reports of comparative treatment efficacies reflect closely the
399 frequencies with which isolates of reduced susceptibility were detected in this work. This
400 in turn suggests that routine susceptibility testing, associated with appropriate
401 interpretation of these data obtained, would be cost-effective and an essential element in
402 the prudent use of antibiotics in aquaculture.

403 Verner-Jeffreys & Taylor (2015) reported that within the UK most batches of
404 rainbow trout were treated with FFN at least once during every production cycle. Thus,
405 given the relatively high frequency of NWT phenotypes detected with respect to the
406 alternative agents available (OXO, OTC and AMOX), it would appear that, as it currently
407 operates, the UK rainbow trout industry is critically dependent on the continued clinical
408 efficacy of FFN. Some concern must be expressed about the long-term sustainability of
409 an industry that would be affected by the emergence of strains of *F. psychrophilum* that
410 were clinically resistant to this agent.

411 As FFN is the agent of choice to treat *F. psychrophilum* infection in many countries,
412 it is reasonable to postulate that this critical dependence of the continued clinical efficacy
413 of FFN is not unique to the UK but is wide-spread in the global trout farming industry.
414 The global situation with respect to FFN susceptibility of *F. psychrophilum* can be
415 assessed from a number of studies that have been published. Studies that have employed
416 standard MIC testing protocols and that generated data of adequate precision have been
417 reported from Denmark and the UK (Smith *et al.* 2016), Chile (Miranda *et al.* 2016) and
418 USA (Van Vliet *et al.* 2017). Studies of the antimicrobial susceptibility of Danish (Bruun
419 *et al.* 2000) and French (Michel *et al.* 2003) *F. psychrophilum* isolates that used non-
420 standardised agar dilution protocols have also been published Combining the data
421 presented in these studies with the data generated in this study provides a total of 829
422 measurements of FFN susceptibility, of which only two (0.2%), both collected in Chile,
423 were categorised as NWT with respect to FFN. Recently the presence of a region
424 containing resistance genes to florfenicol (*floR*), tetracycline (*tetX*), streptothricin and

425 chloramphenicol acetyltransferase gene was detected in *Chryseobacterium* spp. from
426 rainbow trout (Verner-Jeffreys *et al.* 2017). However, this resistance gene cassette was
427 not widely distributed in Flavobacteriaceae isolates (Verner-Jeffreys *et al.* 2017).

428 These data would indicate, rather surprisingly, that the selective pressure that must
429 have resulted from the use of this agent during the 25 or more years since the introduction
430 of the antibiotic to aquaculture (Smith 2008) has not yet resulted in any significant
431 emergence of strains of *F. psychrophilum* strains with reduced susceptibility to this agent.
432 However, it cannot be automatically assumed that this situation will continue. Given the
433 significance of FFN to the global trout farming industry, and as recommended by the
434 World Animal Health Organisations ([http://www.oie.int/international-standard-](http://www.oie.int/international-standard-setting/aquatic-code/access-online)
435 [setting/aquatic-code/access-online](http://www.oie.int/international-standard-setting/aquatic-code/access-online)), it is essential that programmes designed to detect any
436 emergence of isolates of *F. psychrophilum* with reduced susceptibility to this agent are
437 implemented as a matter of urgency by all relevant authorities.

438

439 **Conclusions**

440 Interpretation of MIC data by NRI analysis for *F. psychrophilum* generated by the
441 standardised microdilution protocol (CLSI 2014a) provided an overview of the
442 frequencies of isolates manifesting reduced susceptibility in 118 UK isolates. There was a
443 general agreement between the frequencies of isolates manifesting WT phenotypes for
444 the agents FFN, OXO and OTC, observed in this work, and the reports of their clinical
445 success when used in commercial farms in the UK. On the basis of this, it is strongly
446 recommended that, in order to ensure rational and prudent use of antibiotics to control *F.*

447 *psychrophilum* infections, susceptibility testing using standardised methods should be
448 performed in association with all on-farm administrations of the antibiotics.

449 The Aquatic Animal Health Code of the World Animal Health Organisation
450 recommends that all relevant authorities should implement programmes for the
451 monitoring and surveillance of the susceptibility of aquatic animal pathogens to
452 antibiotics used in their areas. As the UK trout farming industry is critically dependent on
453 the continued efficacy of FFN in the control of RTFS, the implementation of such a
454 programme with respect to *F. psychrophilum* would appear to be a priority for the UK.
455 The standardised MIC susceptibility testing protocol of CLSI and the epidemiological
456 cut-off values developed in this work would provide the analytical methods for such a
457 programme.

458

459 **Acknowledgements**

460 This work was supported by the EU project TARGETFISH, Targeted Disease
461 Prophylaxis in European Fish Farming, under FP7 (grant no. 311993). Special thanks are
462 expressed to Dr Robin Wardle from MSD Animal Health for generously donating
463 Sensititre CMP1MSP plates; Mr Richard Hopewell from Dawnfresh Farming, Dr Tim
464 Wallis from Ridgeway Biologicals, Dr Matthijs Metselaar from Fish Vet Group and Dr
465 Margaret Crumlish from the Bacteriology laboratory, University of Stirling for providing
466 clinical *F. psychrophilum* strains.

467

468 **References**

469 Baquero F. (1990) Resistance to quinolones in gram-negative microorganisms:
470 mechanism and prevention. *European Urology* **17**, 3-12.

471 Barnes M.E. & Brown M.L. (2011) A review of *Flavobacterium psychrophilum* biology,
472 clinical signs, and bacterial cold water disease prevention and treatment. *The Open Fish*
473 *Science Journal* **4**, 40-48.

474 Bauer A.U., Kirby W.M., Sherris J.C. & Track M (1966) Antibiotic susceptibility testing
475 by a standardized single disc method. *Journal of Clinical Pathology* **45**, 493–494.

476 Borg A.F. (1948) Studies on myxobacteria associated with diseases in salmonid fishes.
477 Ph.D. Thesis. University of Washington. Seattle.

478 Boutin S., Bernatchez L., Audet C. & Derôme N. (2012) Antagonistic effect of
479 indigenous skin bacteria of brook charr (*Salvelinus fontinalis*) against *Flavobacterium*
480 *columnare* and *F. psychrophilum*. *Veterinary Microbiology* **155**, 355-361.

481 Boyacıoğlu M. & Akar F. (2012) Isolation of *Flavobacterium psychrophilum* causing
482 rainbow trout fry syndrome and determination of an effective antibacterial treatment in
483 rainbow trout (*Oncorhynchus mykiss*) fry. *Kafkas Üniversitesi Veteriner Fakültesi*
484 *Dergisi* **18**, 197-203.

485 Boyacıoğlu M, Kum C., Kirkan S., Sekkin S., Parin U., Karademir U. & Akar F. (2015)
486 Comparison of *in vitro* and *in vivo* antibacterial efficacy for the control of
487 *Flavobacterium psychrophilum* in rainbow trout (*Oncorhynchus mykiss*) fry: the first
488 genotypical evidence in West Aegean region of Turkey. *Turkish Journal of Veterinary*
489 *and Animal Sciences* **39**, 314-321.

490 Bruun M.S., Schmidt A.S., Madsen L. & Dalsgaard I. (2000) Antimicrobial resistance
491 patterns in Danish isolates of *Flavobacterium psychrophilum*. *Aquaculture* **187**, 201-212.

492 Bruun M.S., Madsen L. & Dalsgaard I. (2003) Efficiency of oxytetracycline treatment in
493 rainbow trout experimentally infected with *Flavobacterium psychrophilum* strains having
494 different in vitro antibiotic susceptibilities. *Aquaculture* **215**, 11-20.

495 Burbank D., LaPatra S., Fornshell G. & Cain K. (2012) Isolation of bacterial probiotic
496 candidates from the gastrointestinal tract of rainbow trout, *Oncorhynchus mykiss*
497 (Walbaum), and screening for inhibitory activity against *Flavobacterium*
498 *psychrophilum*. *Journal of Fish Diseases* **35**, 809-816.

499 Castillo D., Higuera G., Villa M., Middelboe M., Dalsgaard I., Madsen L. & Espejo R.
500 (2012) Diversity of *Flavobacterium psychrophilum* and the potential use of its phages for
501 protection against bacterial cold water disease in salmonids. *Journal of Fish Diseases* **35**,
502 193-201.

503 Cepeda C. & Santos Y. (2000) Rapid and low-level toxic PCR-based method for routine
504 identification of *Flavobacterium psychrophilum*. *International Microbiology* **3**, 235-238.

505 CLSI (2006) *Methods for Antimicrobial Disk Susceptibility Testing of Bacteria Isolated*
506 *from Aquatic Animals*, Approved Guideline VET03-A. Clinical and Laboratory Standards
507 Institute, Wayne, PA.

508 CLSI (2008) *Development of In-Vitro Susceptibility Testing Criteria and Quality Control*
509 *Parameters for Veterinary Antimicrobial Agents: Approved Guideline – third edition*,
510 CLSI document M37-A3. Clinical and Laboratory Standards Institute, Wayne, PA.

511 CLSI (2014a) *Methods for Broth Dilution Susceptibility Testing of Bacteria Isolated from*
512 *Aquatic Animals, Approved Guideline VET04-A2*. Clinical and Laboratory Standards
513 Institute, Wayne, PA.

514 CLSI (2014b) *Performance Standards for Antimicrobial Susceptibility Testing of*
515 *Bacteria Isolated from Aquatic Animals; Second Informational Supplement*. CLSI
516 document VET03/04-S2. Clinical and Laboratory Standards Institute, Wayne, PA.

517 Dalsgaard I. & Madsen L. (2000) Bacterial pathogens in rainbow trout, *Oncorhynchus*
518 *mykiss* (Walbaum), reared at Danish freshwater farms. *Journal of Fish Diseases* **23**, 199-
519 209.

520 Del Cerro A., Márquez I. & Prieto J.M. (2010) Genetic diversity and antimicrobial
521 resistance of *Flavobacterium psychrophilum* isolated from cultured rainbow trout,
522 *Oncorhynchus mykiss* (Walbaum), in Spain. *Journal of Fish Diseases* **33**, 285-291.

523 Durmaz Y., Onuk E.E. & Çiftci A. (2012) Investigation of the presence and antibiotic
524 susceptibilities of *Flavobacterium psychrophilum* in rainbow trout farms (*Oncorhynchus*
525 *mykiss* Walbaum, 1792) in The Middle and Eastern Black Sea Regions of Turkey.
526 *Ankara Üniversitesi Veteriner Fakültesi Dergisi* **59**, 141-146.

527 Gao P., Mao D., Luo Y., Wang L., Xu B. & Xu L. (2012) Occurrence of sulphonamide
528 and tetracycline-resistant bacteria and resistance genes in aquaculture environment.
529 *Water Research* **46**, 2355-2364.

530 Gómez E., Méndez J., Cascales D. & Guijarro J.A. (2014) *Flavobacterium*
531 *psychrophilum* vaccine development: a difficult task. *Microbial Biotechnology* **7**, 414-
532 423.

533 Grape M., Farra A., Kronvall G. & Sundström L. (2005) Integrons and gene cassettes in
534 clinical isolates of co-trimoxazole-resistant Gram-negative bacteria. *Clinical*
535 *Microbiology and Infection* **11**, 185-192

536 Henríquez-Núñez H., Evrard O., Kronvall G. & Avendaño-Herrera R. (2012)
537 Antimicrobial susceptibility and plasmid profiles of *Flavobacterium psychrophilum*
538 strains isolated in Chile. *Aquaculture* **354-355**, 38-44.

539 Hesami S. & Parkman J. (2010) Antimicrobial susceptibility of *Flavobacterium*
540 *psychrophilum* isolates from Ontario. *Journal of Aquatic Animal Health* **22**, 39-49.

541 Izumi S. & Aranishi F. (2004) Relationship between *gyrA* mutations and quinolone
542 resistance in *Flavobacterium psychrophilum* isolates. *Applied and Environmental*
543 *Microbiology* **70**, 3968-3972.

544 Kim J.H., Gomez D.K., Nakai T. & Park S.C. (2010a) Isolation and identification of
545 bacteriophages infecting ayu *Plecoglossus altivelis altivelis* specific *Flavobacterium*
546 *psychrophilum*. *Veterinary Microbiology* **140**, 109-115.

547 Korkea-aho T., Heikkinen J., Thompson K., von Wright A. & Austin B. (2011)
548 *Pseudomonas* sp. M174 inhibits the fish pathogen *Flavobacterium psychrophilum*.
549 *Journal of Applied Microbiology* **111**, 266-277.

550 Kronvall G. (2003) Determination of the real standard distribution of susceptible strains
551 in zone histograms. *International Journal of Antimicrobial Agents* **22**, 7-13.

552 Kronvall G., Kahlmeter G., Myhre E. & Galas M.F. (2003) A new method for normalized
553 interpretation of antimicrobial resistance from disk test results for comparative purposes.
554 *Clinical Microbiology and Infection* **9**, 120-132.

555 Kronvall G. (2010) Normalized resistance interpretation as a tool for establishing
556 epidemiological MIC susceptibility breakpoints. *Journal of Clinical Microbiology* **48**,
557 4445-4452.

558 Kronvall G. & Smith P. (2016). Normalized resistance interpretation, the NRI method.
559 Review of NRI disc test applications and guide to calculations. *ACTA Pathologica*,
560 *Microbiologica et immunologica Scandinavica* **124**, 1023-1030.

561 Kum C., Kirkan S., Sekkin S., Akar F. & Boyacioglu M. (2008) Comparison of *in vitro*
562 antimicrobial susceptibility in *Flavobacterium psychrophilum* isolated from rainbow trout
563 fry. *Journal of Aquatic Animal Health* **20**, 245-251.

564 Lim Y-J., Kim D-H., Roh H.J., Park M-A., Park C-I. & Smith P. (2016) Epidemiological
565 cut-off values for disc diffusion data generated by standard test protocols from
566 *Edwardsiella tarda* and *Vibrio harveyi*. *Aquaculture International*. DOI 10.1007/s10499-
567 016-9977-0

568 Lorenzen E., Dalsgaards I. & Bernardet J-F. (1997) Characterization of isolates of
569 *Flavobacterium psychrophilum* associated with coldwater disease or rainbow trout fry
570 syndrome I: phenotypic and genomic studies. *Diseases of Aquatic Organisms* **31**, 197-
571 208.

572 Michel C., Kerouault B. & Martin C. (2003) Chloramphenicol and florfenicol
573 susceptibility of fish-pathogenic bacteria isolated in France: comparison of minimum
574 inhibitory concentration, using recommended provisory standards for fish bacteria.
575 *Journal of Applied Microbiology* **95**, 1008-1015.

576 Miller R.A. & Reimschuessel R. (2006) Epidemiologic cutoff values for antimicrobial
577 agents against *Aeromonas salmonicida* isolates determined by frequency distributions of
578 minimal inhibitory concentration and diameter of zone of inhibition data. *American*
579 *Journal of Veterinary Research* **67**, 1837-1843.

580 Minoque E., Barry T. Carroll C. & Smith P. (2013) Setting epidemiological cut-off
581 values for *Aeromonas salmonicida* disc diffusion data capable of discriminating between
582 strains on the basis of their possession of *sulI* genes. *Aquaculture* **364-365**, 329-332.

583 Miranda C.D, Smith P., Rojas R., Contreras-Lynch S. & Alonso Vega J.M. (2016)
584 Antimicrobial susceptibility of *Flavobacterium psychrophilum* from Chilean salmon
585 farms and their epidemiological cut-off values using agar dilution and disk diffusion
586 methods. *Frontiers in Microbiology*. Doi: 10.3389/fmicb.2016.01880.

587 Ngo T.P.H., Bartie K.L., Thompson K.D., Verner-Jeffreys D.W., Hoare R. & Adams A.
588 (2017) Genetic and serological diversity of *Flavobacterium psychrophilum* isolates from
589 salmonids in United Kingdom. *Veterinary Microbiology*. Doi:
590 10.1016/j.vetmic.2017.01.032

591 Nilsen H., Johansen R., Colquhoun D.J., Kaada I., Bottolfsen K., Vågnes Ø. & Olsen A.
592 B. (2011) *Flavobacterium psychrophilum* associated with septicaemia and necrotic
593 myositis in Atlantic salmon *Salmo salar*: a case report. *Diseases of Aquatic Organisms*
594 **97**, 37-46.

595 Pacha R.E. (1968) Characteristics of *Cytophaga psychrophila* (Borg) isolated during
596 outbreaks of bacterial cold-water disease. *Applied Microbiology* **16**, 97-101.

597 Prescott J. F. (2007) Sulfonamides, diaminopyrimidines, and their combinations. In:
598 Antimicrobial Therapy in Veterinary Medicine 4th edition, Wiley-Blackwell, pp. 249-262

599 Rangdale R.E., Richards R.H. & Alderman D.J. (1997) Minimum inhibitory
600 concentrations of selected antimicrobial compounds against *Flavobacterium*
601 *psychrophilum* the causal agent of rainbow trout fry syndrome (RTFS). *Aquaculture* **158**,
602 193-201.

603 Romero J., Feijoó C. G. & Navarrete P. (2012) Antibiotics in aquaculture – use, abuse
604 and alternatives. In Health and Environment in Aquaculture, InTech, 159-198.

605 Schmidt A.S., Bruun M.S., Dalsgaard I., Pedersen K. & Larsen J.L. (2000) Occurrence of
606 antimicrobial resistance in fish-pathogenic and environmental bacteria associated with
607 four Danish rainbow trout farms. *Applied and Environmental Microbiology* **66**, 4908-
608 4915.

609 Silley P. (2012) Susceptibility testing methods, resistance and breakpoints: what do these
610 terms really mean? *Scientific and Technical Review of the Office International des*
611 *Epizooties* **31**, 33-41.

612 Smith, P. (2008). “Antimicrobial resistance in aquaculture” in *Changing Trends in*
613 *Managing Aquatic Animal Disease Emergencies*, ed. E.-M. Bernoth (Paris: OIE), **27**,
614 243–264.

615 Smith P. & Kronvall G. (2014) Estimating the precision of disc diffusion antibiotic
616 susceptibility data published by the European Committee on Antimicrobial Susceptibility
617 Testing. *APMIS* DOI: 10.1111/am.12262 (in press).

618 Smith P. & Kronvall G. (2015) Effect of incubation temperature and time on the
619 precision of data generated by antibiotic disc diffusion assays. *Journal of Fish Diseases*
620 **38**, 629-536.

621 Smith P, Ruane N.M., Douglas I., Carroll C., Kronvall G. & Flemming G.T.A. (2007)
622 Impact of inter-lab variation on the estimation of epidemiological cut-off values for disc
623 diffusion susceptibility test data for *Aeromonas salmonicida*. *Aquaculture* **272**, 168-179.

624 Smith P., Schwarz T. & Verner-Jeffreys DW. (2012). Use of normalised resistance
625 analyses to set interpretive criteria for antibiotic disc diffusion data produce by
626 *Aeromonas* spp. *Aquaculture* **326–329**, 27-35.

627 Smith P., Alday-Sanz V., Matysczak J., Moulin G., Lavilla-Pitogo C.R. & Prater D.
628 (2013) Monitoring and surveillance of antimicrobial resistance in mircoorganisms
629 associated with aquatic animals. *Scientific and Technical Review* **32**, 583-593.

630 Smith P., Endris R., Kronvall G., Thomas V., Verner-Jeffreys D., Wilhelm C. &
631 Dalsgaard I. (2016) Epidemiological cut-off values for *Flavobacterium psychrophilum*
632 MIC data generated by a standard test protocol. *Journal of Fish Diseases* **39**, 143-154.

633 Soltani M., Shanker S. & Munday B.L. (1995) Chemithery of *Cytophaga/Flecibacter-*
634 like bacteria (CFLB) infections in fish: studies validating clinical efficacies of selected
635 antimicrobials. *Journal of Fish Diseases* **18**, 555-565.

636 Soule M., Lafrentz S., Cain K., Lapatra S. & Call D.R. (2005) Polymorphisms in 16S
637 rRNA genes of *Flavobacterium psychrophilum* correlate with elastin hydrolysis and
638 tetracycline resistance. *Diseases of Aquatic Organisms* **65**, 209-216.

639 Stenholm A.R., Dalsgaard I. & Middelboe M. (2008) Isolation and characterization of
640 bacteriophages infecting the fish pathogen *Flavobacterium psychrophilum*. *Applied and*
641 *Environmental Microbiology* **74**, 4070-4078.

642 Ström- Bestor M. & Wiklund T. (2011) Inhibitory activity of *Pseudomonas* sp. on
643 *Flavobacterium psychrophilum*, *in vitro*. *Journal of Fish Diseases* **34**, 255-264.

644 Sundell K., Heinikainen S. & Wiklund T. (2013) Structure of *Flavobacterium*
645 *psychrophilum* populations infecting farmed rainbow trout *Oncorhynchus mykiss*.
646 *Diseases of Aquatic Organisms* **103**, 111-119.

647 Toyama T., Kita-Tsukamoto K. & Wakabayashi H. (1994) Identification of *Cytophaga*
648 *psychrophila* by PCR targeted 16S ribosomal RNA. *Fish Pathology* **29**, 271-275.

649 Valdebenito S. & Avendaño-Herrera R. (2009) Phenotypic, serological and genetic
650 characterization of *Flavobacterium psychrophilum* strains isolated from salmonids in
651 Chile. *Journal of Fish Diseases* **32**, 321-333.

652 Van Vliet D., Loch T.P., Smith P. & Faisal M. (2017) Antimicrobial susceptibilities of
653 *Flavobacterium psychrophilum* isolates from the Great Lakes Basin, Michigan. *Microbial*
654 *Drug Resistance*. Doi:10.1089/mdr.2016.0103.

655 Verner-Jeffreys D.W. & Taylor N.J. (2015) Review of freshwater treatments used in the
656 Scottish freshwater rainbow trout aquaculture industry. *Scottish Aquaculture Research*
657 *Forum Report SARF100*

658 Verner-Jeffreys, D.W., Brazier, T., Perez, R.Y., Ryder, D., Card, R.M., Welch, T.J.,
659 Hoare, R., Ngo, T., MacLaren, N., Ellis, R., Bartie, K.L., Feist, S.W., Rowe, W.M.P.,
660 Adams, A. & Thompson, K.D. (2017) Detection of the florfenicol resistance gene *floR* in

661 *Chryseobacterium* isolates from rainbow trout. Exception to the general rule? *FEMS*

662 *Microbiol Ecol.* Doi: 10.1093/femsec/fix015.

663

664 **Table 1.** Summary of 118 UK *F. psychrophilum* isolates analysed in this study

Location	Host source	No. of sites	Site	Year of isolation	No. of sampling times	No. of strains	No. of genotypes (*)	No. of plasmid profiles (*)
Scotland	RT(93)/ AS(14)	20		2005-2015	46	102	47	7
			Scot I	2005-2014	16	25	11	4
			Scot II	2013	1	1	1	1
			Scot III	2011-2015	4	13	9	4
			Scot IV	2013	1	5	2	2
			Scot V	2013-2015	4	27	16	5
			Scot VI	2009	1	1	1	1
			Scot VII	2007	1	1	1	1
			Scot VIII	2005	1	1	1	1
			Scot IX	2006	1	1	1	1
			Scot X	2011-2013	2	3	2	1
			Scot XI	2015	1	4	3	1
			Scot XII	2010	1	1	1	1
			Scot XIII	2005	1	1	1	1
			Scot XIV	2013	1	2	1	1
			Scot XV	2013	2	3	2	1
			Scot XVI	2014-2015	4	9	4	3
			Scot XVII	2007	1	1	1	1
			Scot XVIII	2009	1	1	1	1
			Unknown (2)	2009-2012	2	2	2	2
England	RT	6		2007-2015	8	13	5	2
			Eng I	2013	3	8	4	2
			Eng II	2015	1	1	1	1
			Eng III	2015	1	1	1	1
			Eng IV	2015	1	1	1	1
			Eng V	2007	1	1	1	1
			Eng VI	2007	1	1	1	1
Northern Ireland	RT	1	N Ire I	2013	2	3	2	2
Total	RT(111)/ AS(14)			2005-2015	56	118	51	7

665 RT, rainbow trout; AS, Atlantic salmon

666 (*) Genotypes and plasmid profiles of *F. psychrophilum* isolates determined by Ngo *et al.* (2017).

667

668

669 **Table 2.** Fifteen *F. psychrophilum* isolates from outside the UK used in this study
 670

Countries	Host source	Year of isolation	No. of strains	No. of genotypes ^a	No. of plasmid profiles ^a
Chile	RT	1995-1997	2	2	2
Denmark	RT	1990-1994	3	3	1
Finland	RT	1996	2	2	1
France	RT	unknown-2013	3	2	1
Ireland	AS	2006	1	1	1
USA ^b	RT(3)/CS(1)	unknown - 2004	4	4	2
Total	RT(13)/AS(1)/CS(1)	unknown - 2013	15	13	3

671 RT, rainbow trout; AS, Atlantic salmon; CS, coho salmon

672 ^a Pulsotypes and plasmid profiles of *F. psychrophilum* isolates determined by Ngo *et al.* (2017).

673 ^b including the *F. psychrophilum* type strain NCIMB 1947^T

674

675

676 **Table 3.** MIC values (mg L⁻¹) determined for 133 *F. psychrophilum* isolates

	Off scale	0.002	0.004	0.008	0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	Off scale	
β lactams																	
AMOX	93	Shaded area									19	13	8				
AMP	24	Shaded area					66	3			15	17	8				
Macrolides																	
ERY	4	Shaded area								4	24	93	8				
Phenicols																	
FFN		Shaded area						1	9	69	54						
Quinolones																	
ENRO				7	10	3	3	51	17	14	28	Shaded area					
FLUQ		Shaded area				3	16	1	1	3	41	13	13	Shaded area		42	
OXO		Shaded area					7	13	1	1	6	47	Shaded area			58	
Tetracyclines																	
OTC		Shaded area				12	40	4		2		7	33	32	Shaded area		3
	Off scale	0.002	0.004	0.008	0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	Off scale	

677 Shaded areas indicate MIC values could not be determined using Sensititre CMP1MSP plates.

678 Off scale indicates the number of strains whose MIC lay outside of the range that could be determined using these plates.

679

680

681 **Table 4.** MIC values (mg L⁻¹) determined for potentiated sulphonamide drugs against 133 *F. psychrophilum* isolates

682

	Off scale	0.008/0.15	0.015/0.30	0.03/0.59	0.06/1.19	0.12/2.38	0.25/4.75	0.5/9.5	1/19	2/38	4/76	Off scale
PRI						1	2	15	28	43	29	15
SXT					1	11	37	30	48			6

683

684 Shaded areas indicate MIC values could not be determined using Sensititre CMP1MSP plates.

685 Table 5. Cut-off values (CO_{WT}) calculated using NRI from 133 MIC observations

Agent	Number of WT observations	Standard deviation ^a (log ₂ mg L ⁻¹)	CO _{WT} (mg L ⁻¹)
AMP ^b	93 (70%)	ND ^c	≤ 0.125
ENRO	20 (15%)	0.74	≤ 0.032
ERY	133 (100%)	0.98	≤ 8
FFN	133 (100%)	0.68	≤ 2
FLUQ	20 (15%)	0.57	≤ 0.125
OTC	56 (42%)	0.68	≤ 0.25
OXO	21 (16%)	0.67	≤ 0.25
PRI	133 (100%)	1.39	≤ 16/304
SXT	133 (100%)	1.61	≤ 8/152

686 ^a Standard deviation of the normalised distribution of MIC values for WT strains.

687 ^b CO_{WT} value of AMP was estimated by visual examination.

688 ^c ND: not determined

689

690

691 Table 6. Provisional cut-off values (CO_{WT}) calculated using NRI from 133 inhibition zone
692 observations

Agent	Number of WT observations	Standard deviation* (mm)	CO _{WT} (mm)
AMOX ₁₀	90 (68%)	5.20	≥ 56
FFN ₃₀	133 (100%)	5.61	≥ 45
OTC ₃₀	65 (49%)	7.44	≥ 51
OXO ₂	20 (15%)	8.50	≥ 30

693 * Standard deviation of the normalised distribution of MIC values for WT strains.





694

695

696

697

698



722

723

724

725


726

727

728

729

730



731

732


733

734

735

736

737



738 **Figure 1.** Distribution of 133 *F. psychrophilum* strains according to inhibition zone

739 diameters generated by disc diffusion method for 30 µg oxytetracycline (A, OTC₃₀),

740 10 µg amoxicillin (B, AMOX₁₀), 30 µg florfenicol (C, FFN₃₀), 2 µg oxolinic acid (D,

741 OXO₂), 5 µg enrofloxacin (E, ENRO₅) and 25 µg trimethoprim/sulphamethoxazole (F,

742 SXT₂₅). The continuous line represents the 8 point rolling means, the vertical dashed

743 line represents the calculated disc diffusion-based cut-off value.

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761


762

763


764

765


766




A



B




C



D

767 **Figure 2.** Plot of 133 paired MIC values versus disc diffusion zone diameters for
 768 oxytetracycline (A), florfenicol (B) and oxolinic acid (C). A continuous thick line
 769 presents the calculated cut-off line of the microbial agent.

770



788 **Figure 3.** Plot of 133 paired MIC values between antimicrobial agents within beta-
 789 lactam group (A: ampicillin and amoxicillin) and quinolone group (B: oxolinic acid
 790 and flumequine; C: oxolinic acid and enrofloxacin). A continuous thick line presents
 791 the calculated cut-off line of the microbial agent. A dashed line presents an estimated
 792 cut-off value.